Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...

In commemoration of World Cancer Day 2025, global biopharmaceutical company AstraZeneca has reinforced its dedication to advancing ...

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in ...

AstraZeneca has reinforced its commitment to advancing cancer care through early detection, innovative treatments, and equitable healthcare access in recognition of World Cancer Day 2025 under the ...

JOHANNESBURG: In recognition of World Cancer Day 2025, AstraZeneca reaffirms its commitment to advancing early detection, ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Patients with CKD who use antiresorptive drugs for tumor-related disorders or oral corticosteroids may be at increased risk for osteonecrosis of the jaw.

The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

In this video, Xiuning Le, MD, PhD, discusses how she approaches putting together a treatment plan for a patient with EGFR-mutated lung cancer.

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...